Rapid risk assessment: Regional outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019
A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.
Rapid risk assessment: Multidrug-resistant Staphylococcus epidermidis
This rapid risk assessment addresses the public health risk associated with a previously unrecognised international spread of near pandrug-resistant strains of S. epidermidis as a cause of infection in several countries including EU Member States.
Rapid risk assessment: Carbapenemase-producing (OXA-48) Klebsiella pneumoniae ST392 in travellers previously hospitalised in Gran Canaria, Spain
This rapid risk assessment evaluates the risk of transmission and further spread of OXA-48-producing Klebsiella pneumonia e ST392 from travellers having sought medical care in Gran Canaria to healthcare facilities in their country of origin in the EU/EEA.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
Proposals for EU guidelines on the prudent use of antimicrobials in humans
Proposal for EU guidelines on the prudent use of antimicrobials in human medicine, including generic principles of good practice on the appropriate use of antimicrobial agents in human medical practice in the EU.
Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016
This risk assessment provides an overview of the epidemiological situation in Europe and describes a number of response options.
Last-line antibiotics are failing: options to address this urgent threat to patients and healthcare systems
This briefing aims to draw the attention of policymakers to examples of measures that can be taken at national and local levels to halt the spread of highly resistant bacteria, especially those resistant to ‘last-line’ antibiotics.
Rapid Risk Assessment: Plasmid-mediated colistin resistance in Enterobacteriaceae, 15 June 2016
This document assesses the risk for patients and healthcare systems in the EU/EEA due to the global mcr-1 plasmid-mediated gene epidemic.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.